Medicare AdvantagePrior AuthHigh impact
Angiotensin Blocking Agents (Revised)
Humana·Cardiology, Internal Medicine, Family Medicine +2 more·Medicare Advantage
We identified it
Jul 22, 2026
Summary
Unable to provide complete analysis. This policy change involves Step Therapy requirements for Angiotensin Blocking Agents under Medicare Advantage plans, but only a summary-level reference is available. The actual policy content, specific step therapy requirements, affected drug codes, and effective date are not accessible from the source provided.
Action Required
URGENT: Billing team must immediately access the full policy document at https://dctm.humana.com/Mentor/Web/v.aspx?objectID=090009298a586814 to obtain: (1) specific HCPCS codes for angiotensin blocking agents affected, (2) step therapy requirements and sequence, (3) prior authorization procedures, (4) effective date. Until full policy content is reviewed, claims for angiotensin blocking agents may be at risk of denial. Assign this task to the billing compliance officer immediately given the 1-day-old policy status and high priority flag.